BioCryst announced that the Brazilian Health Regulatory Agency, or ANVISA, has granted approval for oral, once-daily Orladeyo for the prophylaxis of hereditary angioedema, or HAE, attacks in adults and pediatric patients 12 years of age or older. BioCryst has an exclusive collaboration with Pint Pharma to register and promote Orladeyo in the pan-Latin America region. Under the terms of the agreement, Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing Orladeyo in the region.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst to Present at Upcoming Investor Conferences
- New Regulation Risk for BioCryst Pharmaceuticals – What’s the Latest?